Companies › Suzhou Zelgen Biopharmaceuticals
6 active drug programs in 24 registered trials: 20 Phase 1, 2 Phase 3, 2 Phase 2; Oncology, Immunology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ZG006 | – | Phase 3 | Small-cell Lung Cancer; Neuroendocrine Carcinoma; Small Cell Lung Cancer | Dec 2026 |
| Jaktinib Hydrochloride Tablet JAK inhibitor | JAK1, JAK2, JAK3 | Phase 3 | Atopic Dermatitis | – |
| ZG005 Unclear - biological investigational drug for solid tumors | – | Phase 2 | Advanced Solid Tumor; Biliary Tract Carcinoma; Lymphoma; Non-small Cell Lung Cancer … | Apr 2027 |
| ZGGS18 | – | Phase 1 | Advanced Solid Tumor | Nov 2026 |
| Gecacitinib Tyrosine kinase inhibitor targeting EGFR | EGFR | Phase 1 | Healthy; Lymphoma; Non-small Cell Lung Cancer; Cervical Cancer … | Feb 2027 |
| ZGGS34 anti-MUC17 monoclonal antibody | MUC17 | Phase 1 | Solid Tumor | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05526222 | Jaktinib Hydrochloride Tablet | Phase 3 | Atopic Dermatitis | Immunology | Aug 2025 |
| NCT06440057 | ZG006 | Phase 1 | Neuroendocrine Carcinoma | Oncology | May 2026 |
| NCT05978284 | ZG006 | Phase 1 | Small Cell Lung Cancer | Oncology | Sep 2026 |
| NCT05584800 | ZGGS18 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2026 |
| NCT06592638 | ZG006 | Phase 1 | Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT07565597 | Gecacitinib | Phase 1 | Healthy | Other | Feb 2027 |
| NCT07012304 | Gecacitinib | Phase 1 | Chronic Graft Versus Host Disease | Immunology | Feb 2027 |
| NCT06283719 | ZG006 | Phase 1 | Small Cell Lung Cancer | Oncology | Apr 2027 |
| NCT06883526 | ZG005 | Phase 1 | Lymphoma | Oncology | Apr 2027 |
| NCT06903377 | ZG005 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Apr 2027 |
| NCT06883526 | Gecacitinib | Phase 1 | Lymphoma | Oncology | Apr 2027 |
| NCT06903377 | Gecacitinib | Phase 1 | Non-small Cell Lung Cancer | Oncology | Apr 2027 |
| NCT06938880 | ZGGS18 | Phase 1 | Advanced Solid Tumor | Oncology | May 2027 |
| NCT06927687 | ZG005 | Phase 2 | Advanced Solid Tumor | Oncology | May 2027 |
| NCT06938880 | ZG005 | Phase 1 | Advanced Solid Tumor | Oncology | May 2027 |
| NCT07080216 | ZG005 | Phase 1 | Cervical Cancer | Oncology | Aug 2027 |
| NCT07080216 | Gecacitinib | Phase 1 | Cervical Cancer | Oncology | Aug 2027 |
| NCT07038096 | ZG006 | Phase 1 | Small Cell Lung Cancer | Oncology | Sep 2027 |
| NCT07038096 | ZG005 | Phase 1 | Small Cell Lung Cancer | Oncology | Sep 2027 |
| NCT07099547 | ZG005 | Phase 2 | Biliary Tract Carcinoma | Oncology | Dec 2027 |
| NCT07189455 | ZG006 | Phase 3 | Small-cell Lung Cancer | Oncology | Oct 2028 |
| NCT07883382 | Gecacitinib | Phase 1 | Myeloid Neoplasms With Myelofibrosis | Oncology | Oct 2028 |
| NCT07231445 | ZG006 | Phase 1 | Small Cell Lung Cancer | Oncology | Dec 2028 |
| NCT07258121 | ZGGS34 | Phase 1 | Solid Tumor | Oncology | Dec 2028 |
Dizal Pharmaceuticals Hansoh BioMedical R&D Company Shanghai JMT-Bio Jiangsu Alphamab Biopharmaceuticals Jiangsu Aosaikang Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.